DEVELOPMENT AND EVALUATION OF RANITIDINE HYDROCHLORIDE FLOATING TABLET
HTML Full TextReceived on 19 August, 2013; received in revised form, 14 November, 2013; accepted, 26 December, 2013; published 01 January, 2014
DEVELOPMENT AND EVALUATION OF RANITIDINE HYDROCHLORIDE FLOATING TABLET
Radhika D. Ingale*, Vinod M. Thakare, Bharat W. Tekade and Vijay R. Patil
TVES’s Honourable Loksevak Madhukarrao Chaudhari College of Pharmacy, Faizpur, Tal- Yawal, Dist- Jalgaon, Maharashtra, India
ABSTRACT: Floating matrix tablets of ranitidine hydrochloride were developed and evaluated to increase bioavailability by increasing gastric residence time and sustained release of drug in the upper part of gastrointestinal tract thereby diminishing side effects and enhanced patient compliance. The tablets were prepared by direct compression method, using polymers such as Hydroxy propyl methyl cellulose, carbopol 940, xanthum gum, oryza sativa husk, chitosan and cetyl alcohol. The formulations were evaluated for various physical parameters, buoyancy studies, dissolution parameters and drug released profile from all formulation batch F8 showed slow and sustained release of ranitidine hydrochloride over a period of 12 hours upto 95%. Optimized floating matrix tablets F8 showed no change in physical appearance, drug content, or in dissolution pattern after storage at 40±2°C/75±5% for 90 days. It was concluded that formulation F8 shows the better buoyancy and drug release.
Keywords: |
Ranitidine hydrochloride, Floating Matrix tablet, Sustained release, In vitro buoyancy
INTRODUCTION:Through current release technology, oral delivery for 24 h is possible for many drugs; however, the substance must be absorbed well throughout the whole gastrointestinal tract. A significant obstacle may arise if there is a narrow window for drug absorption in the gastrointestinal tract, if a stability problem exists in gastrointestinal fluids, or the drug is poorly soluble in the intestine or acts locally in the stomach. Thus, the real challenge in the development of oral controlled release dosage forms is not just to prolong the delivery of the drugs for more than 12 h, but to prolong the presence of the dosage forms in the stomach or somewhere in the upper small intestine until all the drug is released for the desired period of time 1.
The gastro retentive drug delivery system can be retained in the stomach and assist in improving the oral sustained delivery of drug that have an absorption window in a particular region of the gastrointestinal tract. These systems help in continuously releasing the drug before it reaches the absorption window, thus ensuring optimal bioavailability 2, 3.
Several approaches are currently used to prolong gastric retention time. These include floating drug delivery systems, also known as hydrodynamically balanced systems, swelling and expanding systems, polymeric bioadhesive systems, modified-shaped systems, high density systems, and other delayed gastric emptying devices 4, 5.
Ranitidine hydrochloride is a histamine H2- receptor antagonist. It is widely prescribed in active duodenal ulcers, gastric ulcers, Zollinger- Ellison syndrome, gastroesophageal reflux disease and erosive esophagitis 6, 7. The recommended adult oral dosage of ranitidine is 150 mg twice daily or 300 mg once daily.
The effective treatment of erosive esophagitis requires administration of 150 mg of ranitidine 4 times a day. A conventional dose of 150 mg can inhibit gastric acid secretion up to 5 h but not up to 10 h. An alternative dose of 300 mg leads to plasma fluctuations; thus a sustained release dosage form of ranitidine hydrochloride is desirable 8. The drug has a short biological half-life of approximately 2–3 h, an absolute bioavailability of only 50%, and it is absorbed only in the initial part of the small intestine also favors development of a sustained release formulation 9.
The objective of the present study was to develop and evaluate floating matrix tablets of ranitidine hydrochloride to achieve prolong gastric retention, enhance drug bioavailability and to sustained the release of ranitidine hydrochloride in the stomach, by using Hydroxymethylcellulose, carbopol 940, xanthum gum, chitosan, oryza sativa husk and cetyl alcohol.
MATERIALS AND METHODS:
Materials: Ranitidine hydrochloride was received as a gift sample from Hindustan Lab., Palghar, India. Hydroxypropyl methylcellulose, Chitosan, Xanthan gum, cetyl alcohol, Oryza sativa husk and Carbopol 940 were received as gift samples from Loba Chemical, Mumbai, India. All other ingredients were of laboratory grade.
Methods: Ranitidine floating tablets were prepared by direct compression technique. Drugs and polymers were accurately weighed and blended thoroughly using glass mortar and pestle manually in geometric proportion was mixed thoroughly. Lactose, talc, and magnesium stearate were added to the above blend. The powder blends were evaluated for the properties such as loose bulk density, tapped bulk density, compressibility index and angle of repose. The composition of different formulations of floating tablets is shown in table 1.
TABLE 1: COMPOSITION OF FLOATING MATRIX TABLETS OF RANITIDINE HYDROCHLORIDE
Ingredient | F1 | F2 | F3 | F4 | F5 | F6 | F7 | F8 |
Ranitidine HCL | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 |
HPMC K15M | 20 | - | 20 | 20 | 20 | 20 | - | - |
HPMC K100M | 100 | 100 | 100 | 100 | 100 | 100 | 200 | 100 |
Carbopol 940 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 |
XG | - | - | - | 10 | 20 | 20 | 20 | 20 |
Chitosan | 10 | 10 | 10 | 10 | 10 | 10 | 10 | |
OSH | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 |
PVA | 10 | 10 | 10 | 10 | 10 | - | - | - |
Cetostearyl Alcohol | - | - | 3% | 3% | 3% | - | - | - |
Cetyl alcohol | - | - | - | - | - | 3% | 3% | 3% |
Evaluation of Floating Matrix Tablet:
Hardness: Tablet was placed between two anvils of hardness tester; force was applied to the anvils and the crushing strength that just cause the tablet to break was recorded. Hardness was sometimes termed as tablet crushing strength.
Thickness and Diameter: It was determined for five tablets from a batch by using a calibrated Vernier Callipers and the result was given in mm.
Friability: The friability of uncoated tablets was determined by using Electrolab friabilator in the laboratory. This device subjects a number of tablets to the combined effects of abrasion and shock by utilizing a plastic chamber that revolves at 25 rpm, dropping the tablets a distance of six inches with each operation for 100 revolutions.
The tablets was then dusted and reweighed. It is expressed as the loss of mass and it is calculated as a percentage of initial mass. The values for both Hardness & Friability can together indicate the mechanical strength of tablet.
Weight Variation Test: Weight variation of tablets was calculated by weighing 20 tablets individually and determining the average weight. Tablet meets the test if not more than two of the individual weights deviate from percentage limits 10.
Drug Content Uniformity: 10 tablets were weighed and triturated. The tablet triturate equivalent to 100 mg of the drug was weighed accurately, dissolved in pH 1.2 buffers and diluted to 100 ml with the same.
Further dilutions were done suitably to get a concentration of 10mcg/ml with simulated gastric fluid pH 1.2. Absorbance was read at 313nm against the blank 11.
Swelling Studies: Tablet were weighed individually (recorded as W1) and placed separately in Petri dish containing 5 mL of Hydrocloric acid (pH 1.2) solution. At regular intervals (1, 2, 3, 4 and 5 hours), the tablets was removed from the Petri dish and excess surface water was removed carefully using the filter paper. The swollen tablets were then reweighed (W2), and swelling index (SI) was calculated using formula as 12;
Swelling Index =
In vitro Floating Study: The in vitro floating behavior of the tablets was studied by placing them in 900 ml of plastic containers filled with 900 ml of 0.1 N HCl. (pH 1.2, 37 ± 0. 5oC). The floating lag times (time period between placing the tablet in the medium and tablet floating) and floating durations of the tablets were determined by visual observation 13.
In vitro Dissolution Studies: In-vitro drug release studies of Ranitidine hydrochloridewere studies using dissolution apparatus USP type II paddle method with a stirring speed of 50 rpm at 37 ± 0.5oC in 900 ml 0.1 N HCl for 12 hours. The samples were taken at pre-selected time intervals with replacement of equal volume of dissolution media. The collected samples were diluted and the absorbance was measured spectrophotometrically at 313 nm. The percentage of Ranitidine Hydrochloride released at various time intervals were calculated from the standard graph and the kinetic release model was fitted on dissolution data14.
RESULT AND DISCUSSION:
Precompression Parameter: The prepared powder mixtures were evaluated for the blend property like an Angle of repose, Bulk density, Tapped density and compressibility index Hausner’s ratio.
The results of bulk density & tapped density were showed good flow properties of powder. The results were showed in the table 2.
TABLE 2: EVALUATION OF PRE-COMPRESSION PARAMETERS OF FORMULATIONS F1-F8
Formulations | Bulk Density*(± SD) | Tapped Density*(± SD) | Angle of Repose (0) | Carr’s Index | Hausner’s Ratio |
F1 | 0.595± 0.20 | 0.668±0.22 | 26.67±0.49 | 18.75±0.22 | 1.27±0.72 |
F2 | 0.620 ±0.38 | 0.670 ±0.38 | 28.89±0.39 | 20.47±0.46 | 1.12±0.51 |
F3 | 0.639 ±0.26 | 0.718 ±0.29 | 27.13±0.85 | 15.17±0.23 | 1.26±0.49 |
F4 | 0.652 ±0.15 | 0.730 ±0.19 | 29.67±0.45 | 16.39±0.61 | 1.19±0.68 |
F5 | 0.668±0.29 | 0.742 ±0.28 | 26.34±0.81 | 21.65±0.24 | 1.27±0.72 |
F6 | 0.679 ±0.36 | 0.756 ±0.28 | 25.90±0.39 | 19.87±0.47 | 1.17±0.67 |
F7 | 0.712 ±0.29 | 0.778 ±0.39 | 24.23±0.56 | 14.55±0.48 | 1.32±0.56 |
F8 | 0.690 ±0.35 | 0.764 ±0.26 | 30.45±0.85 | 16.10±0.63 | 1.23±0.79 |
Physicochemical Properties: The prepared formulations were evaluated for the physical characteristics like thickness, hardness, friability, weight uniformity. The results obtained are shown in Table 3. The deviation from the average weight was found to be within the prescribed official limits. Hardness of tablets was found to be in the range of 3.2 to 4.6 Kg given in the table 3. The friability of all tablets was found to be in range of 0.52-0.94 which is less than 1% that showed good mechanical strength.
TABLE 3: EVALUATION OF PHYSICOCHEMICAL PROPERTIES OF FORMULATIONS F1-F8
Formulations | Hardness(kg/cm2)* (±SD) | Thickness(mm)* (± SD) | % Friability | % Wt Variation(mg) (n=20) |
Article Information
37
269-274
525KB
1569
English
IJPSR
Radhika D. Ingale*, Vinod M. Thakare, Bharat W. Tekade and Vijay R. Patil
TVES’s Honourable Loksevak Madhukarrao Chaudhari College of Pharmacy, Faizpur, Tal- Yawal, Dist- Jalgaon, Maharashtra, India
radhikaingale@yahoo.com
19 August, 2013
14 November, 2013
26 December, 2013
http://dx.doi.org/10.13040/IJPSR.0975-8232.5(1).269-74
01 January, 2014